Note: EPS may not be comparable

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q4 EPS of ($0.80), $0.02 worse than the analyst estimate of ($0.78). Revenue for the quarter came in at $1.19 million versus the consensus estimate of $1.65 million.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.